|
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. |
70.00% |
|
Experimental Radiology |
70.00% |
|
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. |
70.00% |
|
SONIA POULTON INTERVIEWS DR. MIKAEL NORDFORS CORRUPTED MEDICINE AND ALTERNATIVE TREATMENTS. |
70.00% |
|
Cancer preventive effect of Morinda citrifolia (Noni). |
70.00% |
|
Effects of opioids on the immune system. |
70.00% |
|
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r |
70.00% |
|
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. |
70.00% |
|
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 |
70.00% |
|
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. |
70.00% |
|
Brain tumour cells killed by anti-nausea drug |
70.00% |
|
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer |
70.00% |
|
Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells |
70.00% |
|
Proton Therapy |
70.00% |
|
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline |
70.00% |
|
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. |
70.00% |
|
Cancer Growth and Its Inhibition in Terms of Coherence |
70.00% |
|
Efficacy of ukrain in the treatment of pancreatic cancer. |
70.00% |
|
BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
70.00% |
|
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. |
70.00% |
|
Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. |
70.00% |
|
Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. |
70.00% |
|
Oncologic benefit of tonsillectomy in stage I and II tonsil cancer: a surveillance epidemiology and end results database review |
70.00% |
|
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines |
70.00% |
|
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. |
70.00% |
|
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). |
70.00% |
|
Cyberknife |
70.00% |
|
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re |
70.00% |
|
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
|
Oireachtas Special Committee on COVID-19 Response |
70.00% |
|
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. |
70.00% |
|
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... |
70.00% |
|
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. |
70.00% |
|
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. |
70.00% |
|
Digitoxin and its analogs as novel cancer therapeutics. |
70.00% |
|
New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? |
70.00% |
|
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu |
70.00% |
|
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal ca. patients |
70.00% |
|
Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial |
70.00% |
|
The efficacy of corticosteroids in restoring hearing in patients undergoing conservative management of acoustic neuromas.' |
70.00% |
|
The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial. |
70.00% |
|
Medical Cannabis Compounds |
70.00% |
|
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. |
70.00% |
|
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. |
70.00% |
|
Hyperthermia and Immunity. A Brief Overview |
70.00% |
|
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes |
70.00% |
|
Energy metabolism, proteotoxic stress and age-related dysfunction - protection by carnosine. |
70.00% |
|
Focal laser ablation of prostate cancer: definition, needs, and future |
70.00% |
|
Enhanced anticancer potential of encapsulated solid lipid nanoparticles of TPD: a novel triterpenediol from Boswellia serrata. |
70.00% |
|
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. |
70.00% |
|
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre |
70.00% |
|
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone |
70.00% |
|
Novel dammarane-type sapogenins from Panax ginseng berry and their biological activities. |
70.00% |
|
Boswellia serrata: An Overall Assessment of In Vitro, Preclinical, Pharmacokinetic and Clinical Data. |
70.00% |
|
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. |
70.00% |
|
Oncolytic virus therapy for prostate cancer. |
70.00% |
|
Association between serum 25(OH)D and death from prostate cancer. |
70.00% |
|
Ukrain treatment in a patient with breast carcinoma |
70.00% |
|
Increased risk of cancer subsequent to severe depression--a nationwide population-based study. |
70.00% |
|
The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways |
70.00% |
|
Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. |
70.00% |
|
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. |
70.00% |
|
Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. |
70.00% |
|
Radiosurgery for spinal malignant tumors. |
70.00% |
|
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. |
70.00% |
|
Novel strategies to reverse chemoresistance in colorectal cancer |
70.00% |
|
Clinical results of N-acetylcysteine after major hepatic surgery: a review. |
70.00% |
|
Epidemiologic evidence on coffee and cancer. |
70.00% |
|
Anti-cancer drugs that target metabolism, is dichloroacetate the new paradigm? |
70.00% |
|
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer |
70.00% |
|
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. |
70.00% |
|
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot |
70.00% |
|
Garlic, or Allium sativum: a review of its potential use as an anti-cancer agent. |
70.00% |
|
Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain |
70.00% |
|
Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. |
70.00% |
|
Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis. |
70.00% |
|
Radiofrequency ablation |
70.00% |
|
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli |
70.00% |
|
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. |
70.00% |
|
Hypoxia in cancer: significance and impact on clinical outcome. |
70.00% |
|
Local ultrasound hyperthermia as a component of radiotherapy for osteogenic sarcoma of tubular bones in children and adolescents |
70.00% |
|
Homeopathy as a supportive therapy in cancer. |
70.00% |
|
Animal studies on Ukrain |
65.00% |
|
Albarin, Injectable Aloe Vera or Polymannons |
65.00% |
|
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. |
65.00% |
|
Chelidonium majus L. (Ukrain) in the treatment of cancer patients. |
63.33% |
|
Evaluation of Ukrain as an immunostimulant in patients with various carcinomas. |
63.33% |
|
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can |
63.33% |
|
Ukrain |
62.22% |
|
Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angio.. |
60.00% |
|
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. |
60.00% |
|
Unconventional anticancer agents: a systematic review of clinical trials. |
60.00% |
|
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare |
60.00% |
|
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. |
60.00% |
|
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. |
60.00% |
|
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of |
60.00% |
|
Focal therapy for prostate cancer: revolution or evolution? |
60.00% |
|
Pycnogenol may alleviate adverse effects in oncologic treatment. |
60.00% |
|
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and |
60.00% |
|
Systematic review of the treatment of cancer-associated anorexia and weight loss. |
60.00% |
